AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05222763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-assisted patient education intervention designed according to the self-regulation model
Description: Implementation of patient education with the website created about care and compliance needs in mastectomy patients obtained as a result of qualitative research.
Study NCT05222763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The website where the mastectomy patients handbook
Description: The site where the patient booklet is available as pdf
Study NCT06339619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: 20mg/kg ivgtt D1 Q3W
Study NCT06339619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 250mg PO QD
Study NCT06339619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: dosing based on body surface area：BSA\<1.25m2,40mg; BSA=1.25～1.5m2,50mg; BSA>1.5m2, 60mg，PO QD D1-21 Q3W
Study NCT06494527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG002C0106
Description: RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
Study NCT06494527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RG002C0106
Description: RG002C0106 is a siRNA drug targeting complement C3 to silence the related gene through the RNA interfering mechanism and inhibit the expression of C3 protein.
Study NCT05155241 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online health promotion video
Description: Participants will watch an online health promotion video tailored to their current stage of change related to seasonal influenza vaccination uptake once every two weeks for four times (at week 0, 2, 4, and 6)
Study NCT05155241 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control (same online health promotion video)
Description: Participants will watch a same online video providing general advices related to seasonal influenza vaccination at week 0, 2, 4, and 6
Study NCT05486117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib
Description: Cream for topical application 20 mg/g
Study NCT05580419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4PCP Course
Description: 4PCP is a training framework for the management of chronic pain and gives practitioners lasting knowledge on how to better care for chronic pain patients.
Study NCT04982146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 20mg per mL of total tumor volume calculated, administered percutaneously
Study NCT05814081 — intervention group
Intervention type: PROCEDURE
Intervention: Position/Ventilation
Description: Positioning and ventilation mode adjustments were made to the patients.
Study NCT06403865 — intervention group
Intervention type: DRUG
Intervention: Cabotegravir, Rilpivirine Drug Combination
Description: Treatment switch to CAB+RPV LA
Study NCT05722600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grape juice
Description: Hardaliye (grape juice) is a fermented, traditional non-alcoholic beverage made from fresh grapes. It is mainly produced by the fermentation of grapes, sour cherry leaves and mustard seeds. Hardaliye was purchased from traditional producers in Turkey. Hardaliye Group consumed 250 ml/day of hardaliye (grape juice) for 28 days.
Study NCT05722600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Placebo drink has carbohydrate, energy and sensory properties similar to hardaliye. Placebo Group consumed 250 ml/day of placebo drink
Study NCT06461208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encapsulated FMT
Description: Encapsulated Faecal Microbiota Transplant
Study NCT06461208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product contains microcrystalline methylcellulose. It is supplied as a size 0, Swedish Orange Delayed-Release capsule (DRCap) and provides a complete match with regards to the appearance (e.g., dimensions, colour) to the FMT capsules.
Study NCT06021977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
Study NCT05587088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petiveria Alliacea Preparation
Description: Petiveria Alliacea Preparation in pill
Study NCT05587088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in pill
Study NCT05140733 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar foraminal decompression
Description: lumbar foraminal decompression with endoscopic instruments.
Study NCT05140733 — intervention group
Intervention type: PROCEDURE
Intervention: Fusion surgery
Description: Fusion surgery for patients with foraminal stenosis
Study NCT06372028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation (tVNS)
Description: tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
Study NCT06372028 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcutaneous vagus nerve stimulation (tVNS)
Description: tVNS allows the non-invasive stimulation of the Vagus Nerve by delivering electrical pulses to the sensory afferent fibers of the auricular, thick-myelinated, branch of the vagus nerve in the outer ear. TVNS seems to engage the same neural pathways of invasive VNS methods and may provide a novel, bottom-up NIBS method to enhance gamma-aminobutyric acid and Noradrenaline levels, which play a pivotal role in brain plasticity. The stimulation will be performed by using a Conformite Europeenne (CE) marked tVNS device tVNS®E (tVNS, technologies Gesellschaft mit beschränkter Haftung (GMBH), Erlangen, Germany). It consists in a programmable stimulation unit connected to two titan ear electrodes that are mounted on a gel frame, allowing to generate and transfer electric impulses from the stimulation unit to the surface of the skin, where the electrodes are applied.
Study NCT05437198 — intervention group
Intervention type: OTHER
Intervention: collection of human exhalation
Description: the collection of the exhalation will be carried out with a non-invasive device manufactured by a Chinese company.~The collection of exhalation consists of the subject inhaling through the nose and exhaling gently through the mouth through a plastic straw for a time set at 5 min in the device
Study NCT04719767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: visual laryngeal mask
Description: After anesthesia induction, visual laryngeal mask airway was placed in the visual group and tracheal intubation was guided under visual conditions. In the non-visual group, laryngeal mask airway was inserted, after clinical judgment of good counterpoint of the laryngeal mask, endotracheal intubation was inserted blindly through LMA. Selection of laryngeal mask airway (LMA) model: the ideal body weight of the patient was calculated.
Study NCT05761223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ia dose-escalation part of FB849 Monotherapy
Description: At a given level dose once daily
Study NCT05761223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase Ib dose-expansion of FB849 monotherapy
Description: At recommended dose for expansion cohort once daily
Study NCT05761223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Study NCT05761223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer)
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Study NCT05761223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer)
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Study NCT05761223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)
Description: At recommended dose for expansion cohort once daily in combination with pembrolizumab
Study NCT05103696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Remazolam 7mg for the first time (push time 1min), 2.5mg can be added after 2min according to MOAA/S score, no more than 5 times within 15min
Study NCT05103696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etomidate combined with propofol
Description: Etomidate 0.1mg/kg+1% propofol 0.5mg/kg for the first time ,etomidate0.05mg/kg+ 1% propofol 0.25 mg/kg can be added according to MOAA/S score
Study NCT04497909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness online training
Study NCT05579158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application and wearable device
Description: Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity
Study NCT05579158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile application and wearable device
Description: Mobile application-supported nutritional counseling includes education, monitoring, interaction, and physical activity
Study NCT05579158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Time-restricted eating (an 8-hour period (from 10 a.m. to 6 p.m.) each day)
Study NCT04830956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface
Study NCT04830956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane Hydration
Description: Drops applied to the ocular surface
Study NCT04668586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:YAG laser machine
Description: Ureteroscopy with Holmium:YAG laser lithotripsy
Study NCT04668586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber laser machine
Description: Ureteroscopy with Thulium Fiber laser lithotripsy
Study NCT06389019 — intervention group
Intervention type: OTHER
Intervention: Deep learning system for prognostication prediction in bladder cancer
Description: develop and validate a deep learning system for prognostication prediction in bladder cancer based on CT radiomics and whole slide images.
Study NCT06248931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic acid
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive valproate 500-1000 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of valproate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT06248931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients will receive topiramate 50-100 mg daily and Acetaminophen 500-1000 mg only in acute migraine attacks for 3 months. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of topiramate was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05506501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral epidural anesthesia
Description: Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia using unilateral epidural anesthesia.
Study NCT05506501 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided femoro/ sciatic nerve block
Description: Forty patients with low ejection fraction (30-40%) will do elective insertion of nail tibia for fixation of fracture shaft tibia by femoral/sciatic nerve block using ultrasound guidance.
Study NCT06509178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peyton group
Description: The same procedures were applied to the students in the experimental group as the students in the control group, except for laboratory applications. Students were asked to watch the video contents after the theoretical course, and in the laboratory practice, sterile urinary catheter application was taught to the students according to Peyton's 4-step approach. Before the skill demonstration, students were given information about the research. Students were given 15-20 minutes to fill out the voluntary consent form and the urinary catheterization success pre-test. Students were taught the sterile urinary catheter procedure in accordance with Peyton's 4-step approach.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
Study NCT06509178 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Halsed group
Description: After the control group students attended the course in accordance with the routine procedures, the students were asked to watch videos of the online urinary catheter application course and the students were taught how to apply sterile urinary catheter using the Halsted method (see one and do it), which is traditionally used in laboratory practice. Students were informed about the research and voluntary consent forms were obtained. Students were given 15-20 minutes to complete the urinary catheterization success pre-test. During the demonstration, the students' questions were answered, the researcher went over the points that the student did not understand, corrected any incorrect behavior, and gave feedback. Afterwards, each student was asked to demonstrate the skill steps individually.The research was conducted on the days and hours of the students' laboratory days. The data collection phase of the research took 3 weeks in total.
Study NCT05147883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Patients will be given an aerobic exercise program for 1 hour, 3 days a week for 12 weeks
Study NCT06214871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Transcranial Magnetic Stimulation
Study NCT05981911 — intervention group
Intervention type: DEVICE
Intervention: XIENCE Skypoint™ stent
Description: Percutaneous coronary intervention with Xience-Skypoint™ stent
Study NCT04233736 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral lumbar erector spinae plane block
Description: Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
Study NCT04233736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral lumbar erector spinae plane block
Description: Bilateral lumbar erector spinae plane blocks performed under ultrasound guidance
Study NCT05918939 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg
Description: Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) contains purified S protein of SARSCoV-2 - Dose: 5 µg, aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005%, Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial~(1 ml per vial). The vial should be shaken well before injection.
Study NCT05918939 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
Description: Control vaccine in this study is existing CoronaVacBioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.
Study NCT05227222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-device
Description: PEP-device
Study NCT06306885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation plus motor imagery followed by sleep
Description: Participants will be asked to observe video-clips showing motor contents immediately before sleeping
Study NCT06306885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action observation plus motor imagery
Description: Participants will be asked to observe video-clips showing motor contents at least 12 hours before sleeping
Study NCT06306885 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will be asked to observe video-clips showing landscapes before sleeping
Study NCT05274984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the control group will be given the same volume of saline.
Study NCT05274984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: the experimental group will be given 1.5mg/kg lidocaine and then 2mg/kg/h
Study NCT06064656 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: No study treatment will be administered on this study.
Study NCT05283304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine injection (BUP-Inj)
Description: Sublingual Buprenorphine induction, then SublocadeTM, Indivior injectable (300mg)
Study NCT05283304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Sublingual buprenorphine induction, then Placebo injectable (300 mg)
Study NCT04720222 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENA-PROTO1
Description: Each volunteer will test the TENA-PROTO1 according to a standardized protocol in multiple postural positions to evaluate the detectability of the bladder by help of the investigational device
Study NCT05689723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar manipulation
Description: Left and right sidelyiing gaping high velocity low amplitude thrust mobilization
Study NCT05689723 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Manipulation
Description: The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension PROM without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
Study NCT06075238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blinatumomab
Description: The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
Study NCT05516823 — intervention group
Intervention type: OTHER
Intervention: Usage of drugs
Description: Self-reported past usage of drugs belonging to different chemical groups.
Study NCT04803136 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: spine surgeries
Description: all spine surgeries including stabilization and fusion surgeries
Study NCT05564351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye mask and ear plug
Description: black eye mask and silicon ear plug
Study NCT05292820 — intervention group
Intervention type: OTHER
Intervention: Validated and non-validated questionnaire for exploration of sexuality and satisfaction after surgical procedure
Description: Validated questionnaire : Female Sexual Function Index (FSFI), Female Genital Self-Imaging Scale (FGSIS), Body Image Scale (BIS), Non-validated questionnaire exploring post-surgery satisfaction, self-esteem scale, sexology.
Study NCT05016856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Promotion With Person-centered Technology (APPT) System
Description: A personalized and adaptive text message reminder system.
Study NCT05016856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Reminder System (Active Control)
Description: A typical text message reminder system.
Study NCT05073887 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Current Targets
Description: blockade and radio frequency stimulation of genicular nerves
Study NCT05073887 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Targets
Description: blockade and radio frequency stimulation of genicular nerves
Study NCT05255081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adspray
Description: Application of AdSpray™ over all organs under the laparotomy incision at the end of operation